Defense Biotechnology Strategy Act
- Bill Number
- H.R. 6009
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Armed Forces and National Security
- Status
- Introduced
- Latest Action
- 2025-11-10: Referred to the Committee on Armed Services, and in addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-01-08T09:06:33Z
AI-Generated Summary
Purpose
The Defense Biotechnology Strategy Act (H.R. 6009) aims to address national security risks and opportunities from emerging biotechnologies—such as genetic engineering and biological manufacturing—by requiring the Department of Defense (DoD) to create a comprehensive strategy. This strategy will outline biotechnology's future role in defense and ways to strengthen ties with industry, other government agencies, and international partners.
Key Provisions
- Development and Submission of Strategy: Within one year of enactment, the Secretary of Defense must submit a strategy to the Senate and House Armed Services Committees. It will be developed in coordination with the Under Secretary of Defense for Research and Engineering (who oversees innovation and technology development) and the Under Secretary for Acquisition and Sustainment (who manages procurement and supply chains).
- Required Elements of the Strategy:
- Building a network of commercial facilities for biomanufacturing defense-critical products, like medical supplies or materials.
- Reviewing and updating military specifications (standards for equipment and materials) to include or replace traditional items with biotechnology-based alternatives.
- Creating plans for advance market commitments (pre-agreements to buy products) and offtake agreements (contracts to purchase output) for biotech products with defense uses.
- Integrating military applications of biotech into planning tools, such as wargaming exercises (simulated conflict scenarios), tabletop exercises (discussion-based simulations), or net assessment analyses (evaluations of strategic strengths and weaknesses).
- Assessing the pros and cons of launching a "research grand challenge" (a major competitive funding initiative) to make biotechnology more reliably engineerable, including how to implement it.
- Establishing a DoD program for biotechnology regulation science and technology, including digital tools for easier oversight and biometrology tools (measurement standards for biological products).
- Developing policies to support NATO (North Atlantic Treaty Organization) member countries in combining their buying power for biotech products.
- Reviewing and updating plans for sharing biotech research across NATO countries, including coordination with international partners to leverage collective research strengths.
Significant Changes to Existing Law
This bill introduces a new mandate for the DoD to produce a dedicated biotechnology strategy, which does not appear to exist in current law. It expands DoD's focus on biotech by requiring specific actions like commercial partnerships, regulatory programs, and NATO collaborations, building on but going beyond existing defense innovation authorities (e.g., under the National Defense Authorization Act). No repeals or direct amendments to prior laws are specified.
Potential Impacts
- Government Agencies: The DoD will need to allocate resources for strategy development, potentially increasing coordination with agencies like the Department of Health and Human Services for biotech regulation. This could streamline procurement and innovation but add administrative burdens.
- Citizens: Indirect benefits may include enhanced national security through advanced biotech defenses (e.g., faster vaccine production or bio-based materials), potentially improving military readiness and public health responses to threats like bioweapons.
- International Relations: Strengthens U.S. leadership in biotech alliances, particularly with NATO allies, by promoting shared research and purchasing. This could foster global standards but raise concerns about technology sharing or dependencies on foreign biotech supply chains.
Main Stakeholders Affected
- Department of Defense and Military: Primary implementers, including research, acquisition, and policy offices.
- Biotechnology Industry: Commercial firms involved in biomanufacturing and research, benefiting from contracts, facilities, and market commitments.
- Congressional Committees: Armed Services Committees for oversight; Foreign Affairs Committee for international aspects.
- NATO and International Partners: Allied governments and researchers, through collaborative initiatives.
- Broader Research Community: Universities and labs focused on biotech, potentially via grand challenges.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill reinforces DoD's authority under existing statutes to pursue emerging technologies for defense, with no apparent conflicts. It emphasizes voluntary international coordination, avoiding treaty-level commitments.
- Constitutional: Aligns with Congress's power to regulate the military and foreign affairs (Article I, Section 8), promoting executive branch strategy without infringing on separation of powers.
- Political: Highlights bipartisan interest in biotech as a national security priority (introduced by representatives from both parties), potentially influencing future defense budgets and U.S. competitiveness against rivals like China in biological technologies. It could spark debates on ethical biotech uses (e.g., genetic engineering in warfare) or regulatory burdens on industry.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Houlahan, Chrissy [D-PA-6]
Cosponsors (2)
Rep. Sessions, Pete [R-TX-17], Rep. Fitzpatrick, Brian K. [R-PA-1]
Recent Actions
- 2025-11-10: Referred to the Committee on Armed Services, and in addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-11-10: Referred to the Committee on Armed Services, and in addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-11-10: Introduced in House
- 2025-11-10: Introduced in House
Bill Versions
- Defense Biotechnology Strategy Act — issued 2025-11-10 — PDF (4 pages)